English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Pharma & Biotech BioTech (Sci&Research)
嘉和生物成功登陸香港聯交所主板
Oct 07, 2020 12:02 HKT
嘉和生物成功登陆香港联交所主板
Oct 07, 2020 12:00 HKT
天大藥業收購瑤池醫療及瑤池養生並達成深度合作
Oct 07, 2020 11:00 HKT
天大药业收购瑶池医疗及瑶池养生并达成深度合作
Oct 07, 2020 11:00 HKT
China Biotech Services (8037.HK) and National Institute for Viral Disease Control and Prevention (NIVDC) to develop Genetically Engineered Recombinant Vaccine for COVID-19
Oct 05, 2020 21:30 HKT
中国生物科技服务(8037.HK)与中国疾控中心病毒病研究所合作 开发新一代新冠病毒基因工程重组疫苗
Oct 05, 2020 20:04 HKT
中國生物科技服務(8037.HK)與中國疾控中心病毒病研究所合作 開發新一代新冠病毒基因工程重組疫苗
Oct 05, 2020 20:02 HKT
Impact BioMedical to Begin Efficacy Testing Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary Innate Immune, Inc.
Oct 05, 2020 15:25 HKT
中國生物科技服務(8037.HK)獲中國疾控中心轉讓新冠病毒基因工程重組疫苗技術
Oct 05, 2020 09:30 HKT
Holista Signs Agreement with Costanzo's to Launch World's Lowest Glycaemic Index (GI) Clean Label Bread
Oct 01, 2020 15:00 HKT
知臨集團開設傳染病液體活檢初創子公司,獨家獲得了新加坡Accelerate Technologies的許可以共同開發基於基因組分析以追蹤病原體基因組的快速分子病原體診斷技術
Sep 29, 2020 18:36 HKT
Aptorum Group Launches Infectious Disease Liquid Biopsy Subsidiary, Announces Exclusive In-license from Singapore-based Accelerate Technologies to Co-Develop Molecular Based Rapid Pathogen Diagnostics to Track Pathogenic Genome
Sep 29, 2020 18:35 HKT
君实生物特瑞普利单抗(拓益®)一线治疗鼻咽癌III期临床研究达到主要研究终点
Sep 29, 2020 09:48 HKT
Insumate(R)--Patented Peptide Sequence mcIRBP-19: a Boon for Diabetics Says Greenyn Biotechnology
Sep 28, 2020 16:00 HKT
노보텍 (Novotech), 파마 인텔리전스 (Pharma Intelligence)의 사이트라인 어워드 2020 (Citeline Awards 2020) 최종후보로 선정
Sep 28, 2020 14:00 HKT
APOLLOMICS(冠科美博)APL-106治療急性髓系白血病的III期臨床橋接研究獲得中國新藥臨床試驗批件
Sep 28, 2020 08:01 HKT
APOLLOMICS(冠科美博)APL-106治疗急性髓系白血病的III期临床桥接研究获得中国新药临床试验批件
Sep 28, 2020 08:00 HKT
애질렉스 바이오랩스, 세계에서 가장 정확한 칸나비노이드 분석법 개발
Sep 24, 2020 06:00 HKT
Agilex Biolabs开发了世界上最准确的大麻素测定
Sep 23, 2020 13:00 HKT
Agilex Biolabs開發了世界上最準確的大麻素測定
Sep 23, 2020 13:00 HKT
<< Previous  Next >>
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: